Silo Pharma Inc

This management proposal seeks shareholder approval to amend the Company’s Articles of Incorporation to increase authorized common shares from 6,666,667 to 250,000,000. Management and the Board state the increase is intended to give the company flexibility to raise equity capital, support strategic transactions (including mergers, acquisitions and partnerships), grant equity under incentive plans, and pursue other corporate needs without the delay and expense of obtaining further shareholder approval. The company notes a specific near-term objective: enabling financings to support acquisitions of in vitro fertilization clinics to reach cash-flow breakeven. As presented, the amendment would not create a new class or change rights of existing common shares, but would materially expand the pool of shares available for issuance, which could dilute existing holders and reduce their voting power per share. The Board explicitly reserves the discretion, even if shareholders approve, not to file the amendment if it determines it is not in the company’s or shareholders’ best interests, which is a typical operational safeguard. The filing also discloses current outstanding and reserved shares (options, warrants, plan reserves) so investors can assess the magnitude of potential dilution relative to the requested increase. From a governance perspective, shareholders should weigh the need for flexibility and the company’s capital plan (including use of shares in lieu of cash for acquisitions or compensation) against the dilution risk and potential effects on market perception and share price. The Board recommends a FOR vote, citing financing and strategic flexibility as primary rationales; there is no competing shareholder proposal or detailed limits on issuances, so post-approval issuance would be governed by the Board’s fiduciary duties and applicable law. Investors evaluating the proposal should consider the company’s current capital structure, liquidity needs, track record of capital raises or related-party issuances, and whether additional safeguards (pre-approval thresholds, anti-dilution limits, or shareholder approval for material issuances) would be appropriate.

This management proposal asks shareholders to authorize the Board to adjourn the Annual Meeting—either because certain proposals do not receive sufficient votes at the scheduled meeting or because the Board, in its discretion, determines an adjournment is appropriate. The request is procedural and intended to preserve the Board’s ability to solicit additional proxies and reconvene the meeting so that outstanding proposals (such as the Common Stock Increase) can be approved without requiring a separate special meeting. The Company frames the adjournment right as limited (adjournments without notice are allowed only when not more than thirty days and no new record date is fixed), and notes shareholders who have previously submitted proxies may revoke them before the adjourned meeting. Strategically, this proposal reduces the operational and financial risk that the company cannot implement time-sensitive corporate actions because of a failed vote at a single meeting. From a governance standpoint, investors should consider that the adjournment power can be used to obtain additional shareholder support but could also delay finality on contested matters; however, board fiduciary duties and disclosure obligations remain applicable. The Board also discloses it has an interest in this proposal to the extent it relates to a compensatory plan in which directors and officers participate, which indicates a potential overlap of personal and corporate interests. The Board recommends a FOR vote to retain flexibility to consummate critical financing or strategic transactions that depend on shareholder approval. Overall, the proposal is routine in practice but important operationally for low‑vote, thinly held companies where achieving a quorum or majority on non-routine matters can be challenging.